Trial Profile
A Multicenter, Open-label, Phase I Study of SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors:
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Advanced breast cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors SymBio Pharmaceuticals
- 04 Nov 2022 Results assessing the safety, pharmacokinetics, and preliminary antitumor effects of bendamustine hydrochloride for patients with advanced solid tumors, published in the Investigational New Drugs.
- 25 Apr 2021 Status changed from recruiting to completed.
- 02 Aug 2018 New trial record